Kuniyoshi Fukai
Overview
Explore the profile of Kuniyoshi Fukai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
348
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yanagiuchi T, Fukai K, Sogabe K, Iwasaki Y, Hirano K, Kato T, et al.
Catheter Cardiovasc Interv
. 2024 Oct;
104(6):1241-1250.
PMID: 39350479
Background: Despite the widespread use of drug-coated balloons (DCBs) for femoropopliteal (FP) lesions, there is still no consensus on treatment strategies for DCB restenosis. This study aimed to determine the...
2.
Tomura N, Nakagami T, Kikai M, Hamaoka T, Fukai K, Yamaguchi S, et al.
CJC Open
. 2024 Jun;
6(5):755-758.
PMID: 38846441
No abstract available.
3.
Takigami M, Nakanishi N, Tsubata H, Fukai K, Matsubara Y, Yanishi K, et al.
PLoS One
. 2023 Jan;
18(1):e0280683.
PMID: 36706099
Background: Balloon pulmonary angioplasty (BPA) is used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and residual pulmonary hypertension after pulmonary endarterectomy (PEA) to improve hemodynamics, right ventricular function,...
4.
Fukai K, Nakagami T, Hamaoka T, Kikai M, Yamaguchi S
Cardiovasc Interv Ther
. 2021 Oct;
37(3):526-532.
PMID: 34665444
Several trials have shown that paclitaxel drug-coated balloons (DCBs) significantly reduce restenosis rates. However, some reports have shown distal embolisms occurring after DCBs. No study has analyzed the clinical outcomes...
5.
Kadoya Y, Zen K, Fukai K, Matsubayashi K, Yamano M, Yamano T, et al.
Korean Circ J
. 2021 Mar;
51(3):283-285.
PMID: 33655730
No abstract available.
6.
Yamanaka R, Hoshino A, Fukai K, Urata R, Minami Y, Honda S, et al.
Am J Physiol Heart Circ Physiol
. 2020 Sep;
319(5):H1087-H1096.
PMID: 32946259
TIGAR reduces smooth muscle cell autophagy to prevent pulmonary hypertension. 319: H1087-H1096, 2020. First published September 18, 2020; doi:10.1152/ajpheart.00314.2020.-Pulmonary arterial hypertension (PAH) is a refractory disease. Its prognosis remains poor;...
7.
Nakanishi N, Fukai K, Tsubata H, Ogata T, Zen K, Nakamura T, et al.
Heart Lung Circ
. 2018 Sep;
28(4):655-659.
PMID: 30224170
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive disorder with a poor prognosis. Recently, balloon pulmonary angioplasty (BPA) has been reported to be an effective treatment for inoperable patients...
8.
Uchihashi M, Hoshino A, Okawa Y, Ariyoshi M, Kaimoto S, Tateishi S, et al.
Circ Heart Fail
. 2017 Dec;
10(12).
PMID: 29242353
Background: Energy starvation and the shift of energy substrate from fatty acids to glucose is the hallmark of metabolic remodeling during heart failure progression. However, ketone body metabolism in the...
9.
Ariyoshi M, Katane M, Hamase K, Miyoshi Y, Nakane M, Hoshino A, et al.
Sci Rep
. 2017 Mar;
7:43911.
PMID: 28266638
-Amino acids are enantiomers of L-amino acids and have recently been recognized as biomarkers and bioactive substances in mammals, including humans. In the present study, we investigated functions of the...
10.
Suzuki C, Nakamura A, Miura N, Fukai K, Ohno N, Yahata T, et al.
Clin Immunol
. 2017 Feb;
179:17-24.
PMID: 28167306
Kawasaki disease (KD) is a paediatric vasculitis whose pathogenesis remains unclear. Based on experimental studies using a mouse model for KD, we report here that proline-rich protein tyrosine kinase 2...